Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study
Krish Patel, P. L. Zinzani(Istituto di Ematologia di Bologna), D. Lewis(Plymouth Hospital), E. Lech-Marańda(Instytut Hematologii i Transfuzjologi), Kami J. Maddocks(The Ohio State University), Donald E. Tsai(University of Pennsylvania), Deepa Jagadeesh(Roswell Park Comprehensive Cancer Center), P. Abada(Eli Lilly (United States)), Toby A. Eyre(Oxford University Hospitals NHS Trust), J. B. Cohen(Emory University), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Benoît Tessoulin(Centre Hospitalier Universitaire de Nantes), Bita Fakhri(University of California, San Francisco), Minna Balbas(Roswell Park Comprehensive Cancer Center), Sunita D. Nasta(University of Pennsylvania), Yuanyuan Bian(Eli Lilly (United States)), Lydia Scarfò(IRCCS Ospedale San Raffaele), Alvaro J. Alencar(University of Miami), Julie M Vose(University of Nebraska Medical Center), Chaitra S. Ujjani(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Catherine C. Coombs(University of California, Irvine), Chan Y Cheah(Sir Charles Gairdner Hospital), Nirav N Shah(Medical College of Wisconsin), Manish R. Patel(Sarah Cannon), Mei Li(Eli Lilly (United States)), Jennifer R. Brown(Harvard University), Marc S Hoffmann(The University of Kansas Cancer Center), Shuo Ma(Northwestern University), Jennifer A. Woyach(The Ohio State University), Talha Munir(Leeds Teaching Hospitals NHS Trust)
Cited by 1
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k